Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2007

Eden Biodesign and University of Birmingham Ink Therapeutic Deal


  • Eden Biodesign has been selected by the University of Birmingham to develop and produce vOX2:Fc, a therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The university’s David Blackbourn, Ph.D., has been investigating the molecule.

    “Working with Eden Biodesign will allow us to advance our understanding of the therapeutic potential of this drug candidate; clinical applications for this novel therapy could range from autoimmune diseases such as rheumatoid arthritis to asthma and allergy,” notes Dr. Blackbourn.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »